The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction
Open accessAbstract
Background and purpose: Monoamine oxidase inhibitors (MAOI) are known to cause serotonin toxicity (ST) when administered with selective serotonin reuptake inhibitors (SSRI). Methylene blue (methylthionium chloride, MB), a redox dye in clinical use, has been reported to precipitate ST in patients using SSRI. MB was assessed for MAO inhibition and so for its potential to precipitate ST. Experimental approach: Inhibition of purified human MAO was quantified using kinetic assays and visible spectral changes to study the interactions of MB with MAO A. Key results: MB was a potent (tight binding) inhibitor for MAO A. It also inhibited MAO B but at much higher concentration. Interactions of MB with the active site of MAO A were confirmed by its action both as an oxidising substrate and as a one‐electron reductant. Conclusions and implications: MB is a potent reversible inhibitor of MAO A with implications for gut uptake of amines when administered orally. At concentrations reported in the literature after intravenous administration, MAO B would be partially inhibited but MAO A would be completely inhibited. This inhibition of MAO A would be expected to lead to perturbations of 5‐hydroxytryptamine metabolism and hence account for ST occurring when administered to patients on SSRI treatment. British Journal of Pharmacology (2007) 152, 946–951; doi:10.1038/sj.bjp.0707430; published online 27 August 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
The therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363
Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H., & Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg109 · Cited by 1,029
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814
Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders
Binda, C., Newton-Vinson, P., Hubálek, F., Edmondson, D. E., & Mattevi, A. (2002) · Nature Structural Biology · doi:10.1038/nsb732 · Cited by 644
A SPECTROSCOPIC STUDY OF METHYLENE BLUE MONOMER, DIMER, AND COMPLEXES WITH MONTMORILLONITE
Bergmann, K., & O’Konski, C. T. (1963) · The Journal of Physical Chemistry · doi:10.1021/j100804a048 · Cited by 592
De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D. E., & Mattevi, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505975102 · Cited by 527
Henderson, P. J. F. (1972) · Biochemical Journal · doi:10.1042/bj1270321 · Cited by 522
Pharmacokinetics and organ distribution of intravenous and oral methylene blue
Peter, C., Hongwan, D., Küpfer, A., & Lauterburg, B. H. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000124 · Cited by 373
Inhibition of Monoamine Oxidase A by β-Carboline Derivatives
Kim, H., Sablin, S. O., & Ramsay, R. R. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9771 · Cited by 253
Self-citation
Cited by
Methylene blue dye: Toxicity and potential elimination technology from wastewater
Oladoye, P. O., Ajiboye, T. O., Omotola, E. O., & Oyewola, O. J. (2022) · Results in Engineering · doi:10.1016/j.rineng.2022.100678 · Cited by 1,187
Cellular and molecular actions of Methylene Blue in the nervous system
Oz, M., Lorke, D. E., Hasan, M., & Petroianu, G. A. (2011) · Medicinal Research Reviews · doi:10.1002/med.20177 · Cited by 443
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
Finberg, J. P. M., & Rabey, J. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00340 · Cited by 432
“Lest we forget you — methylene blue …”
Schirmer, R. H., Adler, H., Pickhardt, M., & Mandelkow, E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.012 · Cited by 414
MXene as emerging material for photocatalytic degradation of environmental pollutants
Solangi, N. H., Karri, R. R., Mazari, S. A., Mubarak, N. M., Jatoi, A. S., Malafaia, G., & Azad, A. K. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214965 · Cited by 274
Geldasa, F. T., Kebede, M. A., Shura, M. W., & Hone, F. G. (2023) · RSC Advances · doi:10.1039/d3ra01505j · Cited by 263
Tau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 262
Ramsay, R., & Tipton, K. (2017) · Molecules · doi:10.3390/molecules22071192 · Cited by 258
Self-citationMethylene blue and Alzheimer's disease
Oz, M., Lorke, D. E., & Petroianu, G. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.034 · Cited by 257
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
“Patients were also assessed at all visits for suicidal ideation and intent using the Columbia-Suicide Severity Rating Scale [17], and were systematically monitored for potential serotonin syndrome using a rating scale derived from four published diagnostic criteria [18], because of a theoretical potential for serotoni…”
MethodTau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50
Metadata
- Authors
- Ramsay, R. R., Dunford, C., & Gillman, P. K.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 6
- Pages
- 946-951
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2063544942
- Cited by
- 276
- References
- 28
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.